A high-resolution imaging approach that could help in diagnosing Parkinson’s disease by enabling physicians to more easily visualize the substantia nigra, the brain region responsible for controlling movement and whose nerve cells are gradually lost to this disease, is the goal of a research group in Australia. The…
A new computer algorithm that guides intracerebral injections to improve drug delivery to the brain has been developed by researchers at the Massachusetts Institute of Technology. The new technology, dubbed COMMAND (computational mapping algorithms for neural drug delivery), was designed to effectively deliver therapeutic molecules to specific brain structures,…
Levodopa/carbidopa intestinal gel (LCIG), a formulation of levodopa and carbidopa infused into the intestines, can lower the duration of off episodes in people with advanced Parkinson’s disease, and is likely to be especially helpful to those whose daily episodes are long-lasting, an analysis of registry study…
Gocovri (amantadine) can reduce the number and duration of off episodes — periods during which levodopa-based treatments cease to be effective and motor symptoms return — as well as ease dyskinesia in patients with Parkinson’s, according to a post-hoc analysis of Phase 3 trials. These findings were presented…
A new Phase 3 clinical trial will test PhotoPharmics‘ light-based, at-home therapy device — called Celeste — for Parkinson’s disease. The “Celeste Light for PD Trial” — a collaboration between PhotoPharmics and the Center for Health + Technology (CHeT) at the University of Rochester Medical Center — will be conducted at…
People living with Parkinson’s disease report disruptions in care and worsening symptoms due to complications related to COVID-19, according to an online survey conducted by The Michael J. Fox Foundation. The Foundation, in collaboration with leading Parkinson’s researchers, conducted the survey through the online Fox Insight study,…
Problems with vision are more common in older people with Parkinson’s disease than in others of a similar age, and are linked with poorer health outcomes, a study based on U.S. Medicare records found. Fewer than 60% of the more than 285,000 Parkinson’s patients whose data were analyzed, however, had…
SpeechVive recently raised more than $1.5 million to support efforts to increase accessibility for the wearable medical device that improves the speech clarity of Parkinson’s disease patients. Capital from the syndicated funding round was provided by Elevate Ventures, Foundry Investment Fund, Southwest Angel Network, Racine Medical Angels,…
Parkinson’s disease may affect more than 1.6 million people in the United States by 2037, at an estimated annual economic burden of $79 billion, according to a recent study. The study, “Current and projected future economic burden of Parkinson’s disease in the U.S.,” was published in…
A multi-faceted intervention that included staff education, electronic alerts, and requiring new reports, improved the timeliness with which Parkinson’s disease patients were given medication in a hospital setting, a new study reports. This suggests that similar interventions might aid in the timeliness of Parkinson’s treatments in other hospitals. The study, “…
Get regular updates to your inbox.
